Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer


1 Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey
2 Department of Medical Oncology, Medipol University, Istanbul, Turkey
3 Department of General Surgery, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey
4 Department of Radiation Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey

Correspondence Address:
Bala Basak Oven Ustaalioglu,
Selimiye Mahallesi, Şair Nesimi Sokak, Kardeşler Apartment, No: 1, Daire: 4, 34668 Uskudar, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Aim of the Study: Although surgery is considered to be curative treatment, recurrence rates are high in gastric cancer. Adjuvant 5-fluorouracil (5-FU) based chemoradiotherapy has been shown to improve the prognosis. We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer. Materials and Methods: Totally, 104 patients who underwent curative surgery with lymph node resection were evaluated, respectively. Patients were stratified two group based on the adjuvant chemoradiotherapy regimen. Group 1 (n = 46) received XP followed capecitabine with RT (XRT) then XP. Group 2 (n = 58) received 5-FU/LV combined with RT postoperatively. Two groups were compared based on clinicopathological parameters. Factors related with disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Totally, 32 patients had recurrent disease, and there was no difference between two groups. While peritoneal metastasis was more common in XP arm, distant metastasis was commonly seen in 5-FU/LV arm. There was no significant difference between two groups in regard of Grade 3/4 toxicitis; hematologic toxicities were more in 5-FU/LV group than XP arm. In addition, dose modification because of toxicities were more frequent in 5-FU/LV arm (P = 0.003). For all groups, lymph node dissection type was related with DFS, surgical margin and recurrence were important for OS. Conclusion: XP-XRT regimen is well tolerated with lower toxicity compared the standard 5-FU/LV-RT. Although there is no difference with respect to outcome, patients with XP arm without the necessity of intravenous catheter admitted hospital less frequent than bolus5-FU/LV arm.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Ustaalioglu BB
    -  Bilici A
    -  Tilki M
    -  Surmelioglu A
    -  Erkol B
    -  Figen M
    -  Uyar S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed269    
    PDF Downloaded21    

Recommend this journal